Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development company, today reported its results for the quarter ended March 31, 2013.
Recent Highlights:
• BL-7040 (IBD) – Received positive results from a Phase 2 proof-of-concept study to evaluate the effectiveness of BL-7040 for the treatment of inflammatory bowel disease (IBD)
